<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Surgery and Oncology</journal-id><journal-title-group><journal-title xml:lang="en">Surgery and Oncology</journal-title><trans-title-group xml:lang="ru"><trans-title>Хирургия и онкология</trans-title></trans-title-group></journal-title-group><issn publication-format="electronic">2949-5857</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">529</article-id><article-id pub-id-type="doi">10.17650/2686-9594-2022-12-1-49-57</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>LITERATURE REVIEW</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОБЗОР ЛИТЕРАТУРЫ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Stereotactic body radiation therapy in patients with liver oligometastases from colorectal cancer: a systematic review</article-title><trans-title-group xml:lang="ru"><trans-title>Стереотаксическая лучевая терапия при олигометастазах колоректального рака в печень: систематический обзор литературы</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2499-6637</contrib-id><name-alternatives><name xml:lang="en"><surname>Moskalenko</surname><given-names>A. N.</given-names></name><name xml:lang="ru"><surname>Москаленко</surname><given-names>А. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p> 17/1 Baumanskaya St., Moscow 105005, Russia </p></bio><bio xml:lang="ru"><p> Россия, 105005 Москва, Бауманская ул., 17/1 </p></bio><email>mansurgkokod@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Lyadov</surname><given-names>V. K.</given-names></name><name xml:lang="ru"><surname>Лядов</surname><given-names>В. К.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>17/1 Baumanskaya St., Moscow 105005, Russia </p><p>2/1 Barrikadnaya St., Moscow 123242, Russia</p><p>5 Stroiteley Prospekt, Novokuznetsk 654005, Russia </p></bio><bio xml:lang="ru"><p> Россия, 105005 Москва, Бауманская ул., 17/1 </p><p>Россия, 123242 Москва, Баррикадная ул., 2/1 </p><p>Россия, 654005 Новокузнецк, проспект Строителей, 5</p><p> </p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Sagaydak</surname><given-names>I. V.</given-names></name><name xml:lang="ru"><surname>Сагайдак</surname><given-names>И. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>2/1 Barrikadnaya St., Moscow 123242, Russia </p><p>23 Kashirskoe Shosse, Moscow 115478, Russia</p></bio><bio xml:lang="ru"><p>Россия, 123242 Москва, Баррикадная ул., 2/1</p><p>Россия, 115478 Москва, Каширское шоссе, 23 </p></bio><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname> Chernykh</surname><given-names>M. V.</given-names></name><name xml:lang="ru"><surname>Черных</surname><given-names>М. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>23 Kashirskoe Shosse, Moscow 115478, Russia;</p><p>2/4 Bolshaya Pirogovskaya St., Moscow 119435, Russia </p></bio><bio xml:lang="ru"><p>Россия, 115478 Москва, Каширское шоссе, 23 </p><p>Россия, 119435 Москва, Большая Пироговская ул., 2, стр. 4</p></bio><xref ref-type="aff" rid="aff4"/><xref ref-type="aff" rid="aff5"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Britskaya</surname><given-names>N. N.</given-names></name><name xml:lang="ru"><surname>Брицкая</surname><given-names>Н. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p> 17/1 Baumanskaya St., Moscow 105005, Russia </p></bio><bio xml:lang="ru"><p> Россия, 105005 Москва, Бауманская ул., 17/1 </p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">City Clinical Cancer Hospital No. 1, Moscow Healthcare Department</institution></aff><aff><institution xml:lang="ru">ГБУЗ «Городская клиническая онкологическая больница № 1 Департамента здравоохранения Москвы»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Russian Medical Academy of Postgraduate Education, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Novokuznetsk State Medical Institute of Postgraduate Education, a branch of the Russian Medical Academy of Postgraduate Education, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">Новокузнецкий государственный институт усовершенствования врачей – филиал ФГБОУ ДПО «Российская медицинская академия непрерывного  профессионального образования» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff5"><aff><institution xml:lang="en">I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2022-04-13" publication-format="electronic"><day>13</day><month>04</month><year>2022</year></pub-date><volume>12</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>49</fpage><lpage>57</lpage><history><date date-type="received" iso-8601-date="2021-12-27"><day>27</day><month>12</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2022-04-13"><day>13</day><month>04</month><year>2022</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2022, Moskalenko A.N., Lyadov V.K., Sagaydak I.V.,  Chernykh M.V., Britskaya N.N.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2022, Москаленко А.Н., Лядов В.К., Сагайдак И.В., Черных М.В., Брицкая Н.Н.</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="en">Moskalenko A.N., Lyadov V.K., Sagaydak I.V.,  Chernykh M.V., Britskaya N.N.</copyright-holder><copyright-holder xml:lang="ru">Москаленко А.Н., Лядов В.К., Сагайдак И.В., Черных М.В., Брицкая Н.Н.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://onco-surgery.info/jour/article/view/529">https://onco-surgery.info/jour/article/view/529</self-uri><abstract xml:lang="en"><p><bold>The purpose</bold> of the systematic review is to summarize the data regarding safety and efficacy of stereotactic body radiation therapy in patients with oligometastases of colorectal cancer to the liver.Published scientific articles on the topic were identified by searching the databases mEDLInE, Pubmed, EmBASE. The review includes publications reporting on the results of treatment of patients undergoing stereotactic radiation therapy for. The systematic review includes all retrospective and prospective studies found over the past 15 years with at least 10 patients with liver metastases of colorectal origin included and standardized methodology of radiation therapy. We included into the review 20 studies comprising 919 patients. Comparative analysis was complicated because of the absence of control groups in all of the studies. moreover, 16 studies were single-center with heterogeneous groups of patients and various regimens of stereotaxic radiation therapy. Despite this, the researchers achieved 60–100 % rates of one-year local control, 56–100 % one-year overall survival with median overall survival up to 45 months and the number of clinically significant complications less than 10 %.From our point of view, the results of published studies support the safety and efficacy of stereotactic radiation therapy in patients with colorectal cancer and oligometastatic liver disease. we consider stereotactic body radiation therapy to be one of the local control options in case of careful patient selection and the use of modern radiation therapy options. further randomized controlled trials are needed.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Целью</bold> систематического обзора является обобщение мирового опыта применения стереотаксической лучевой терапии у больных с олигометастазами колоректального рака в печень.Опубликованные научные статьи по теме были идентифицированы путем поиска в базах данных mEDLInE, Pubmed, EmBASE. В обзор включены публикации, сообщающие о результатах лечения пациентов, которым проводилась стереотаксическая лучевая терапия по поводу метастатического поражения печени при колоректальном раке. В систематический обзор включены все найденные ретроспективные и проспективные исследования за последние 15 лет с участием не менее 10 больных и стандартизованной методикой лучевой терапии.<bold>В результате</bold> поиска отобрано 20 исследований, включавших 919 больных. Проведение сравнительного анализа затрудняется тем, что все найденные работы не имеют групп контроля, при этом 16 из них являются одноцентровыми исследованиями с разнородными группами больных и режимами стереотаксической лучевой терапии. Исследователями достигнуты показатели однолетнего локального контроля 60–100 % при однолетней общей выживаемости 56–100 % и медиане общей выживаемости до 45 мес при числе клинически значимых осложнений до 10 %. с нашей точки зрения, результаты опубликованных исследований свидетельствуют о безопасности и эффективности данной методики у больных с олигометастатическим поражением печени при колоректальном раке. стереотаксическая лучевая терапия может применяться как один из вариантов локального терапевтического воздействия при тщательном определении показаний, отборе пациентов и применении современных вариантов лучевой терапии. Необходимо проведение дальнейших рандомизированных контролируемых исследований.</p></trans-abstract><kwd-group xml:lang="en"><kwd>stereotactic radiation therapy</kwd><kwd>colorectal cancer</kwd><kwd>oligometastatic liver disease</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>стереотаксическая лучевая терапия</kwd><kwd>колоректальный рак</kwd><kwd>олигометастатическое поражение печени</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Van Cutsem E., Nordlinger B., Adam R. et al. European Colorectal Metastases Treatment Group. Towards a panEuropean consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 2006;42(14):2212–21. DOI: 10.1016/j.ejca.2006.04.012.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Adam R., De Gramont A., Figueras J. et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist 2012;17:1225–39.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Adam R., De Gramont A., Figueras J. et al. Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. Cancer Treat Rev 2015;41:729–41.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Gold J.S., Are C., Kornprat P. et al. Increased use of parenchymal-sparing surgery for bilateral liver metastases fromcolorectal cancer is associated with improved mortality without change in oncologic outcome: trends in treatment over time in 440 patients. Ann Surg 2008;247:109–17.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Nordlinger B., Van Cutsem E., Rougier P. et al. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer 2007;43:2037–45.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Guckenberger M., Lievens Y., Bouma A.B. et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol 2020;21(1):e18–e28. DOI: 10.1016/S1470-2045(19)30718-1.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Hoyer M., Roed H., Traberg Hansen A. et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol 2006;45(7):823–30. DOI: 10.1080/02841860600904854.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Stintzing S., Grothe A., Hendrich S. et al. Percutaneous radiofrequency ablation (RFA) or robotic radiosurgery (RRS) for salvage treatment of colorectal liver metastases. Acta Oncol 2013;52(5):971–7. DOI: 10.3109/0284186X.2013.766362.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Ahmed K.A., Caudell J.J., El-Haddad G. et al. Radiosensitivity differences between liver metastases based on primary histology suggests implications for clinical outcomes after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2016;95(5):1399–404. DOI: 10.1016/j.ijrobp.2016.03.050.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Berber B., Ibarra R., Snyder L. et al. Multicentre results of stereotactic body radiotherapy for secondary liver tumours. HPB (Oxford) 2013;15(11):851–7. DOI: 10.1111/hpb.12044.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Chang D.T., Swaminath A., Kozak M. et al. Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer 2011;117(17):4060–9. DOI: 10.1002/cncr.25997.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Doi H., Uemoto K., Suzuki O. et al. Effect of primary tumor location and tumor size on the response to radiotherapy for liver metastases from colorectal cancer. Oncol Lett 2017;14(1):453–60. DOI: 10.3892/ol.2017.6167.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Vernaleone M., Bonomo P., Di Cataldo V. et al. Robotic stereotactic radiotherapy for liver oligometastases from colorectal cancer: a single-center experience. Radiol Med 2019;124(9):870–6. DOI: 10.1007/s11547-019-01042-8.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Scorsetti M., Comito T., Tozzi A. et al. Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer. J Cancer Res Clin Oncol 2015;141(3):543–53. DOI: 10.1007/s00432-014-1833-x.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Van der Pool A.E., Mendez R.A., Wunderink W. et al. Stereotactic body radiation therapy for colorectal liver metastases. Br J Surg 2010;97(3):377–82.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Lee M.T., Kim J.J., Dinniwell R. et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 2009;27(10):1585–91. DOI: 10.1200/JCO.2008.20.0600.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Goodman B.D., Mannina E.M., Althouse S.K. et al. Long-term safety and efficacy of stereotactic body radiation therapy for hepatic oligometastases. Pract Radiat Oncol 2016;6(2):86–95. DOI: 10.1016/j.prro.2015.10.011.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Stintzing S., Einem J.V., Fueweger C. et al. Long-term survival in patients treated with a robotic radiosurgical device for liver metastases. Cancer Res Treat 2019; 51(1):187–93. DOI: 10.4143/crt.2017.594.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Van De Voorde L., Vanneste B., Houben R. et al. Image-guided stereotactic ablative radiotherapy for the liver: a safe and effective treatment. Eur J Surg Oncol 2015;41(2):249–56. DOI: 10.1016/j.ejso.2014.10.053.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Vautravers-Dewas C., Dewas S., Bonodeau F. et al. Image-guided robotic stereotactic body radiation therapy for liver metastases: is there a dose response relationship? Int J Radiat Oncol Biol Phys 2011;81(3):e39–47. DOI: 10.1016/j.ijrobp.2010.12.047.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Kim H., Gill B., Beriwal S. et al. Costeffectiveness analysis of stereotactic body radiation therapy compared with radiofrequency ablation for inoperable colorectal liver metastases. Int J Radiat Oncol Biol Phys 2016;95(4):1175–83. DOI: 10.1016/j.ijrobp.2016.02.045.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Liu E., Stenmark M.H., Schipper M.J. et al. Stereotactic body radiation therapy for primary and metastatic liver tumors. Transl Oncol 2013;6(4):442–6. DOI: 10.1593/tlo.12448.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Méndez Romero A., de Man R.A. Stereotactic body radiation therapy for primary and metastatic liver tumors: From technological evolution to improved patient care. Best Pract Res Clin Gastroenterol 2016;30(4):603–16. DOI: 10.1016/j.bpg.2016.06.003.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Flamarique S., Campo M., Asín G. et al. Stereotactic body radiation therapy for liver metastasis from colorectal cancer: size matters. Clin Transl Oncol 2020;22(12):2350–6. DOI: 10.1007/s12094-020-02375-x.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Clerici E., Comito T., Franzese C. et al. Role of stereotactic body radiation therapy in the treatment of liver metastases: clinical results and prognostic factors. Strahlenther Onkol 2020;196(4):325–33. DOI: 10.1007/s00066-019-01524-8.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>D’Avila Leite P., Gaya S., Lanciano R. et al. Stereotactic body radiotherapy (SBRT) for colorectal liver metastasis: Clinical outcomes from the international multi-institutional RSSearch Patient Registry. J Clin Oncol 2019;37(15 Suppl):e15040.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Petrelli F., Comito T., Barni S. et al. SBRT for CRC liver metastases. Stereotactic body radiotherapy for colorectal cancer liver metastases: A systematic review. Radiother Oncol 2018;129(3):427–4. DOI: 10.1016/j.radonc.2018.06.035.</mixed-citation></ref></ref-list></back></article>
